Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eiger Biopharma (EIGR)

Eiger Biopharma (EIGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,554
  • Shares Outstanding, K 1,481
  • Annual Sales, $ 13,480 K
  • Annual Income, $ -96,780 K
  • EBIT $ -84 M
  • EBITDA $ -82 M
  • 60-Month Beta 1.83
  • Price/Sales 0.18
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -59.16
  • Most Recent Earnings $-12.31 on 11/09/23
  • Next Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -15.62
  • Growth Rate Est. (year over year) +6,495.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +56.82%
on 04/01/24
7.2641 -76.25%
on 03/11/24
-5.1894 (-75.05%)
since 03/08/24
3-Month
1.1000 +56.82%
on 04/01/24
8.2672 -79.13%
on 03/04/24
-5.7050 (-76.78%)
since 01/10/24
52-Week
1.1000 +56.82%
on 04/01/24
43.3500 -96.02%
on 05/16/23
-22.3350 (-92.83%)
since 04/10/23

Most Recent Stories

More News
Eiger BioPharma: Q3 Earnings Snapshot

Eiger BioPharma: Q3 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Stocks Tread Water Before the Open as U.S. Inflation Data Looms

September S&P 500 futures (ESU23) are down -0.02%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.04% this morning as market participants geared up for a key U.S. consumer inflation report...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
ORCL : 181.24 (+5.51%)
AAP : 38.84 (+1.78%)
AAPL : 222.72 (-0.33%)
WRK : 51.51 (+3.54%)
AV-.LN : 457.800 (-0.37%)
WKHS : 0.7765 (+2.17%)
RCKT : 17.58 (+2.27%)
F : 11.19 (+5.57%)
SQSP : 46.57 (-0.21%)
EIGR : 1.7250 (-9.21%)
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharma: Q2 Earnings Snapshot

Eiger BioPharma: Q2 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)
Eiger BioPharma: Q1 Earnings Snapshot

Eiger BioPharma: Q1 Earnings Snapshot

EIGR : 1.7250 (-9.21%)
Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...

EIGR : 1.7250 (-9.21%)

Business Summary

Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.

See More

Key Turning Points

3rd Resistance Point 2.1033
2nd Resistance Point 2.0017
1st Resistance Point 1.8633
Last Price 1.7250
1st Support Level 1.6233
2nd Support Level 1.5217
3rd Support Level 1.3833

See More

52-Week High 43.3500
Fibonacci 61.8% 27.2105
Fibonacci 50% 22.2250
Fibonacci 38.2% 17.2395
Last Price 1.7250
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar